Stephen Davis
Algemeen Directeur bij ACADIA PHARMACEUTICALS INC.
Vermogen: 3 M $ op 30-04-2024
Actieve functies van Stephen Davis
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ACADIA PHARMACEUTICALS INC. | Algemeen Directeur | 11-03-2015 | - |
Directeur/Bestuurslid | 15-07-2014 | - | |
President | 03-09-2015 | - | |
Comptroller/Controller/Auditor | 15-07-2014 | 22-08-2016 | |
Financieel Directeur/CFO | 15-07-2014 | 03-09-2015 |
Loopbaan van Stephen Davis
Eerdere bekende functies van Stephen Davis
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BELLICUM PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 16-07-2015 | 23-02-2024 |
Independent Dir/Board Member | 16-07-2015 | 23-02-2024 | |
HERON THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-10-2019 | 21-02-2023 |
Independent Dir/Board Member | 01-10-2019 | 21-02-2023 | |
SYNAGEVA BIOPHARMA CORP | Directeur/Bestuurslid | 02-11-2011 | 22-06-2015 |
Independent Dir/Board Member | 02-11-2011 | 22-06-2015 | |
HERON THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-06-2012 | 01-06-2015 |
Operationeel Directeur | 01-05-2013 | 01-06-2015 | |
FURIEX PHARMACEUTICALS INC | Directeur/Bestuurslid | 01-05-2013 | 02-07-2014 |
Independent Dir/Board Member | 01-05-2013 | 02-07-2014 | |
Ardea Biosciences, Inc.
Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Operationeel Directeur | 06-04-2010 | - |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Directeur/Bestuurslid | 27-06-2007 | 04-11-2011 |
Neurogen Corp.
Neurogen Corp. Pharmaceuticals: MajorHealth Technology Neurogen Corp. operated as a drug discovery and development company. The company was headquartered in Branford, CT. | Algemeen Directeur | 04-02-2008 | 01-12-2009 |
Operationeel Directeur | 01-01-1994 | 31-01-2010 | |
Financieel Directeur/CFO | 01-01-1994 | 31-01-2010 | |
President | 01-01-2007 | 01-12-2009 | |
Bedrijfssecretaris | 01-01-1994 | 01-12-2009 | |
░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Stephen Davis
Southern Nazarene University | Undergraduate Degree |
Vanderbilt Law School | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 11 |
Hongkong | 2 |
Operationeel
Director/Board Member | 7 |
Independent Dir/Board Member | 4 |
Chief Operating Officer | 3 |
Sectoraal
Health Technology | 9 |
Consumer Services | 3 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ACADIA PHARMACEUTICALS INC. | Health Technology |
HERON THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 7 |
---|---|
Neurogen Corp.
Neurogen Corp. Pharmaceuticals: MajorHealth Technology Neurogen Corp. operated as a drug discovery and development company. The company was headquartered in Branford, CT. | Health Technology |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
Milbank LLP
Milbank LLP Miscellaneous Commercial ServicesCommercial Services Milbank LLP provides legal services. It serves corporate, finance, financial restructuring, litigation and arbitration, securities, capital markets, trusts, estates, and exempt organizations, and tax markets. The company was founded in 1866 and is headquartered in New York, NY. | Commercial Services |
Ardea Biosciences, Inc.
Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Health Technology |
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Furiex Pharmaceuticals, Inc.
Furiex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Furiex Pharmaceuticals, Inc. operates as a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of drug development programs by advancing them through the drug discovery and development process in a cost-efficient manner. Its drug development programs are designed and driven by a core team with extensive drug development experience. Furiex Pharmaceuticals was founded in 1998 and is headquartered in Morrisville, NC. | Health Technology |
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
- Beurs
- Insiders
- Stephen Davis
- Ervaring